Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytarabine and High-Dose Mitoxantrone for Relapsed/Refractory Hematologic Malignancies
NCT00047021Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2001
- Primary completion
- Aug 2005
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine and mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 2 more, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Event free survival at day 14 (myeloid engraftment). Started Nov 2001; status: completed.
02
Drugs
cytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00047021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047021.